News this year of the sale of PCI Synthesis and Ampac Fine Chemicals to French and South Korean companies, respectively, came as something of a surprise. Both drug contract manufacturing organizations (CMOs) had been doing well, investing in growth and honing a focus on technologies and services that are in high demand.